Best Biotech Stocks 2026: Top Biotechnology Companies for Long-Term Investors

25 juin 2026 mounirmorjani

Introduction

Best biotech stocks 2026 — this is what long-term investors are searching for as the biotechnology sector enters one of its most exciting periods in decades. From revolutionary GLP-1 obesity drugs generating billions in quarterly revenue to gene-editing therapies curing genetic diseases, biotech companies are delivering breakthroughs that are reshaping medicine and creating massive investment opportunities.

The AI in drug discovery market alone is projected to grow from $4 billion in 2026 to over $43 billion by 2035, while the broader AI in pharma and biotech market is expected to reach $154 billion by 2034. These numbers reflect a fundamental transformation in how drugs are discovered, developed, and delivered to patients.

In this guide, we explore the best biotech stocks to buy in 2026 for long-term investors, covering large-cap leaders, gene-editing pioneers, and AI-powered drug discovery companies.

Why Biotech Stocks Are Surging in 2026

Several major trends are fueling biotech growth this year.

The GLP-1 obesity and diabetes drug market is exploding. Eli Lilly reported 56 percent revenue growth in Q1 2026 driven by blockbuster demand for Mounjaro and Zepbound, which together generated over $12.8 billion in a single quarter.

Gene-editing therapies are becoming commercial realities. CRISPR Therapeutics and Vertex Pharmaceuticals are seeing growing adoption of Casgevy, the world’s first CRISPR-based gene therapy, with over 500 patients now initiating treatment globally.

Artificial intelligence is transforming drug discovery. Companies like Recursion Pharmaceuticals are synthesizing 90 percent fewer compounds per program while advancing candidates to development roughly twice as fast as industry standard.

Government and private investment in biotech continues to accelerate, with average deal values in AI-driven biotech increasing from $365 million in 2025 to over $527 million in 2026.

Eli Lilly (LLY) — The GLP-1 Obesity Drug Leader

Eli Lilly is the dominant force in the GLP-1 obesity and diabetes drug market, reporting one of the strongest quarters in pharmaceutical history in Q1 2026.

Q1 2026 revenue surged 56 percent year over year to $19.8 billion, beating analyst expectations by over $2 billion. Mounjaro revenue soared 125 percent to $8.66 billion. Zepbound revenue increased 80 percent to $4.16 billion. The company raised full-year revenue guidance by $2 billion. Eli Lilly now holds a 60.1 percent share of the U.S. obesity and diabetes drug market.

Eli Lilly is also advancing an oral GLP-1 pill called Foundayo, which could dramatically expand the addressable market by making weight loss treatment more convenient for patients who dislike injections.

Risk level is moderate. The stock trades at premium valuations, and competition from Novo Nordisk and other entrants is intensifying.

Best for investors who want exposure to the fastest-growing drug category in the world through the market leader.

Vertex Pharmaceuticals (VRTX) — The Gene Therapy Pioneer

Vertex Pharmaceuticals dominates the cystic fibrosis market and is now expanding into gene therapy, pain management, and kidney disease with a diversifying revenue base.

Full year 2026 revenue guidance is $12.95 billion to $13.1 billion. Q1 2026 revenue rose 8 percent to $2.99 billion. Non-cystic fibrosis products including Casgevy and Journavx are expected to contribute $500 million or more in 2026 revenue. The company’s ALYFTREK launch is driving continued CF patient demand growth.

Vertex represents a rare combination in biotech — a profitable, growing company with an established franchise plus multiple new product launches creating additional revenue streams.

Risk level is moderate. The company is profitable and well-diversified, though heavy dependence on cystic fibrosis revenue remains a consideration.

Best for investors who want a proven biotech company with strong cash flow and expanding therapeutic reach.

CRISPR Therapeutics (CRSP) — The Gene-Editing Revolution

CRISPR Therapeutics is the company behind Casgevy, the world’s first approved CRISPR-based gene therapy for sickle cell disease and beta-thalassemia. The technology represents a potential cure rather than a treatment.

Casgevy generated Q1 2026 revenue of $43 million. Over 500 patients globally have now initiated the Casgevy treatment journey. Revenue is expected to nearly triple in 2026 compared to 2025. The company holds $2.44 billion in cash as of March 2026. A top Wall Street analyst predicts the stock could more than double from current levels.

CRISPR Therapeutics is still in early commercialization but represents one of the most transformative medical technologies in history. If gene editing becomes standard treatment for genetic diseases, the upside potential is enormous.

Risk level is high because the company remains unprofitable and commercialization timelines can be uncertain.

Best for investors who believe in the long-term potential of gene-editing medicine and are willing to hold through commercialization ramp-up.

Regeneron Pharmaceuticals (REGN) — The Innovation Powerhouse

Regeneron is one of the most consistently innovative biotech companies, with multiple blockbuster drugs across ophthalmology, immunology, and oncology.

Q1 2026 revenue increased 19 percent to $3.6 billion. Non-GAAP EPS rose 15 percent to $9.47. Dupixent global net sales grew 33 percent to $4.9 billion. EYLEA HD is showing strong U.S. sales growth. The company anticipates multiple FDA approvals and robust pipeline advancement in 2026.

Regeneron has a proven track record of developing and commercializing blockbuster drugs. With trailing twelve-month revenue approaching $15 billion and multiple growth drivers, the company offers strong fundamentals with continued innovation upside.

Risk level is moderate because the company is profitable with diversified revenue streams, though biosimilar competition for older products is a consideration.

Best for investors who want a proven biotech innovator with strong revenue growth and a deep pipeline.

Amgen (AMGN) — The Biotech Dividend Leader

Amgen is the largest independent biotech company and one of the few in the sector that pays a meaningful dividend while pursuing next-generation therapies including obesity treatments.

Q1 2026 revenue grew 6 percent to $8.62 billion. The company has 16 products showing double-digit sales growth and 17 products annualizing at over $1 billion. Amgen raised its dividend for the fourteenth consecutive year, paying $5.1 billion in dividends in 2025. The MariTide obesity drug candidate is advancing through clinical trials. Management describes 2026 as a springboard year for growth.

Amgen offers something unique among biotech stocks — meaningful income through dividends combined with potential upside from its obesity pipeline. If MariTide succeeds, it could transform the company’s growth trajectory.

Risk level is low to moderate because Amgen is profitable with diversified revenue, though patent expirations on older drugs create headwinds.

Best for income-focused investors who want biotech exposure with dividend payments and upside from the obesity market.

Recursion Pharmaceuticals (RXRX) — The AI Drug Discovery Pioneer

Recursion is a clinical-stage company using artificial intelligence and machine learning to transform how drugs are discovered. The company claims to have reached an inflection point where AI can generate clinical proof and durable value.

The company synthesizes 90 percent fewer compounds per program than industry standard, averaging about 330 versus the typical 2,500 to 5,000 compounds. Programs advance to development candidates roughly twice as fast as traditional approaches. Recursion has five differentiated clinical programs advancing with defined milestones. The company has earned more than $500 million in upfront and milestone payments to date. Cash runway is secured through 2027 following a $2.6 billion convertible notes offering.

Recursion represents a high-risk, high-reward bet on the future of AI-powered drug development. If its approach proves successful at scale, it could fundamentally change pharmaceutical R&D economics.

Risk level is very high because the company has minimal revenue, significant net losses, and its AI-native approach remains unproven at commercial scale.

Best for aggressive investors who believe AI will revolutionize drug discovery and want early exposure to a pure-play AI biotech company.

How to Build a Biotech Portfolio

A balanced biotech portfolio should include exposure across different risk levels and therapeutic areas.

For core holdings with lower risk, Eli Lilly, Vertex, and Regeneron offer proven revenue growth with profitable businesses and strong pipelines.

For income with biotech exposure, Amgen provides a meaningful dividend with continued innovation in obesity and other growth areas.

For high-growth speculative positions, CRISPR Therapeutics and Recursion represent transformative technologies that could deliver outsized returns but carry significant uncertainty.

The key is to allocate more capital to proven companies and less to speculative positions while maintaining exposure to breakthrough potential.

Risks of Investing in Biotech Stocks

Biotech investing carries unique risks that all investors should understand.

Clinical trial failures can cause stocks to drop 50 percent or more overnight. Drug development is inherently uncertain and many programs fail.

Regulatory rejections by the FDA can delay or prevent product launches entirely.

Patent expirations expose companies to generic competition that can rapidly erode revenue.

Political and pricing pressure on drug costs can limit profitability, particularly for high-priced gene therapies and obesity drugs.

Smaller biotech companies may run out of cash before achieving commercial success.

Final Thoughts

The best biotech stocks in 2026 offer investors exposure to some of the most transformative medical technologies in history. From GLP-1 drugs generating nearly $20 billion per quarter to gene therapies curing genetic diseases and AI systems discovering drugs faster than ever before, the biotech sector is delivering on decades of scientific promise.

For long-term investors, building a diversified biotech portfolio across large-cap leaders, gene-editing pioneers, and AI drug discovery companies provides balanced exposure to this high-growth sector while managing risk.

The future of medicine is being built today by these companies. Investors who position themselves wisely can participate in one of the greatest innovation cycles in healthcare history.

Frequently Asked Questions

What is the best biotech stock to buy in 2026?

Eli Lilly is considered the top large-cap biotech due to its 56 percent revenue growth and dominance in the GLP-1 obesity market. For gene therapy exposure, Vertex Pharmaceuticals offers a safer profile with proven profitability.

Are biotech stocks risky?

Biotech stocks range from low risk to very high risk. Large companies like Eli Lilly, Vertex, and Amgen have diversified revenue and profitability. Smaller companies like Recursion carry much higher risk due to unproven business models and ongoing losses.

Is CRISPR Therapeutics a good long-term investment?

CRISPR Therapeutics offers transformative potential with its gene-editing technology. However, the company is still in early commercialization with Casgevy. Investors should view it as a high-risk, high-reward position requiring a long time horizon.

Which biotech stocks pay dividends?

Among major biotech companies, Amgen offers the most significant dividend with 14 consecutive years of growth. Most other pure biotech companies reinvest profits into research rather than paying dividends.

How is AI changing drug discovery in 2026?

AI is reducing the number of compounds needed per program by up to 90 percent and cutting development timelines roughly in half. The AI in drug discovery market is projected to grow from $4 billion in 2026 to over $43 billion by 2035.